Last reviewed · How we verify
FEC-DocGemzar adjuvant chemotherapy
FEC-DocGemzar is a combination chemotherapy regimen that uses multiple cytotoxic agents to kill rapidly dividing cancer cells in the adjuvant (post-surgical) setting.
FEC-DocGemzar is a combination chemotherapy regimen that uses multiple cytotoxic agents to kill rapidly dividing cancer cells in the adjuvant (post-surgical) setting. Used for Adjuvant chemotherapy for early-stage breast cancer.
At a glance
| Generic name | FEC-DocGemzar adjuvant chemotherapy |
|---|---|
| Sponsor | Ludwig-Maximilians - University of Munich |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This regimen combines three chemotherapy drugs: 5-Fluorouracil (5-FU), Epirubicin, and Cyclophosphamide (FEC) followed by Docetaxel and Gemcitabine. The FEC component uses a DNA-damaging anthracycline and alkylating agent approach, while Docetaxel is a microtubule-stabilizing taxane and Gemcitabine is a nucleoside analog. Together, they target cancer cells through multiple mechanisms of cytotoxicity to reduce recurrence risk after surgery.
Approved indications
- Adjuvant chemotherapy for early-stage breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity
- Peripheral neuropathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: